FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease

PRNEWSWIRE CAMBRIDGE, Massachusetts, November 4 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration... [read full story]                    

powered by
Add Comment
There are also 6 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies